Alpha DNA Investment Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$3.36M |
| 2 |
PepsiCo
PEP
|
+$2.81M |
| 3 |
Cigna
CI
|
+$2.06M |
| 4 |
Mondelez International
MDLZ
|
+$2.04M |
| 5 |
Visa
V
|
+$1.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Analog Devices
ADI
|
+$3.27M |
| 2 |
MRSH
Marsh
MRSH
|
+$1.82M |
| 3 |
NextEra Energy
NEE
|
+$1.74M |
| 4 |
Delta Air Lines
DAL
|
+$1.48M |
| 5 |
SLB Ltd
SLB
|
+$1.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.28% |
| 2 | Financials | 12.52% |
| 3 | Healthcare | 7.79% |
| 4 | Consumer Discretionary | 6.91% |
| 5 | Consumer Staples | 5.5% |
Similar funds
Alpha DNA Investment Management's Q1 2023 Portfolio in Review
As of Q1 2023, Alpha DNA Investment Management held 217 positions worth $339M, up 20% from $283M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Alpha DNA Investment Management deployed $48.4M of net new capital in Q1 2023, opening 68 new positions and adding to 42 existing holdings. Its largest new stake was Cigna: 7,075 shares worth $1.81M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 15% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Analog Devices, an estimated $3.27M trimmed.
- Alpha DNA Investment Management's largest Q1 2023 buy was Cigna: 7,075 shares worth $1.81M.
- Alpha DNA Investment Management added most to Cisco in Q1 2023, an estimated $3.36M increase.
- Alpha DNA Investment Management's biggest Q1 2023 reduction was Analog Devices, cutting an estimated $3.27M.
- Alpha DNA Investment Management fully exited Marsh in Q1 2023, selling an estimated $1.82M.
- Alpha DNA Investment Management's ten largest holdings make up 52% of its $339M portfolio in Q1 2023.
- Alpha DNA Investment Management opened 68 new positions and closed 70 in Q1 2023.
- Alpha DNA Investment Management's portfolio value rose 20% quarter-over-quarter to $339M.
Based on Alpha DNA Investment Management's 13F filing for Q1 2023, filed 5 May 2023.